298380 - ABL Bio Inc.

298380 Summary

Biopharma

Stock Price & Overview

₩71,400 +3,800 (+5.62%) Close · Sep 4, 2026 KST

KOSDAQ | ₩KRW | Close: ₩71,400 ≈ US$51 · Market cap ₩4.0tn (≈ $2.9bn)

What kstock analysis is. It reads the Korean news and the DART filing, checks the numbers against the source, and explains what changed and what to watch. It does not issue buy, sell or hold ratings and it does not set price targets. Why not »

298380 Analysis

ABL Bio: One Quarter Was 95% Of Last Year's Revenue

ABL Bio's FY2025 revenue of ₩79.3bn was 95.5% earned in a single quarter, and the following quarter booked exactly zero, which is what a milestone line looks like.

kstock researchSep 1, 1:19 AMBiotechSave

1 piece. Written with AI assistance from Korean-language sources; each links the article it rests on.

Similar to 298380

Symbol	Last Price
128940Hanmi Pharm. Co., Ltd.	₩473,500 +2.8%
000100Yuhan Corporation	₩81,400 +0.0%
028300HLB Co., Ltd.	₩33,750 +2.9%
000250Samchundang Pharm	₩157,000 +1.0%
087010Peptron, Inc.	₩157,300 +7.3%
141080LigaChem Biosciences Inc.	₩92,000 +4.2%
145020Hugel, Inc.	₩244,000 +1.5%
302440SK Bioscience Co., Ltd.	₩37,900 +0.4%
009420Hanall Biopharma Co., Ltd.	₩54,700 +1.5%
310210Voronoi, Inc.	₩153,000 +3.9%

Compare all 48 in Biopharma

What a US investor should know

Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
Daily limitKorean stocks can move at most ±30% in a session before trading halts.
Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.